What the 2026 ADA Meeting Might Reveal About Retatrutide
The American Diabetes Association's 2026 Scientific Sessions could present new data on retatrutide, a triple-agonist that activates GLP-1, GIP, and glucagon receptors. Researchers and clinicians who follow metabolic research are watching for head-to-head comparisons with tirzepatide, the dual GIP/GLP-1 agonist that has set a high bar for weight loss. A 2023 phase 2 trial of retatrutide reported mean weight reductions of up to 24.2% at 48 weeks in people with obesity (Jastreboff 2023). That figure exceeded what tirzepatide achieved in its SURMOUNT-1 trial, where the 15 mg dose yielded about 22.5% weight loss at 72 weeks (Jastreboff 2022). However, cross-trial comparisons are fraught with confounding variables, including differences in study populations, background lifestyle interventions, and titration schedules. The ADA 2026 meeting might offer a more direct look if phase 3 data or dedicated comparative analyses are presented. For those tracking how these agents fit into clinical practice, the recent ACP guidelines positioning tirzepatide as a first-line option add urgency to understanding retatrutide's relative efficacy.
What We Already Know About Retatrutide's Weight Loss Profile
The phase 2 trial published in the New England Journal of Medicine enrolled 338 adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. Participants were randomized to retatrutide (1 mg, 4 mg, 8 mg, or 12 mg) or placebo once weekly. At 48 weeks, the 12 mg group achieved a least-squares mean weight reduction of 24.2%, compared with 2.1% for placebo. Nearly all participants in the 8 mg and 12 mg groups lost at least 5% of body weight, and more than 80% lost at least 15%. These results, while remarkable, came with gastrointestinal side effects that were dose-dependent and led to treatment discontinuation in about 15% of the 12 mg group. A 2024 exploratory analysis of the same trial suggested that retatrutide might also improve liver fat and markers of nonalcoholic steatohepatitis (Sanyal 2024). The glucagon receptor agonism component is thought to enhance energy expenditure and lipid oxidation, potentially differentiating retatrutide from dual agonists like tirzepatide. Still, the long-term safety of chronic glucagon receptor activation remains an open question, particularly regarding glycemic control and cardiovascular outcomes. The phase 3 program, including the TRIUMPH trials, is designed to address these uncertainties, and ADA 2026 could be a venue for early results.
How Tirzepatide Compares in Female-Specific Research
Tirzepatide's efficacy in women has been examined in subgroup analyses of the SURMOUNT trials. A 2023 post hoc analysis of SURMOUNT-1 found that women lost a similar percentage of body weight as men, though absolute weight loss was lower due to lower baseline body weight (Wadden 2023). In SURMOUNT-2, which enrolled people with type 2 diabetes, women on 15 mg tirzepatide lost 14.7% of body weight versus 12.9% for men (Garvey 2023). These differences did not reach statistical significance for sex interaction. Notably, tirzepatide's effects on waist circumference, a surrogate for visceral adiposity, were also comparable between sexes. For women with polycystic ovary syndrome, a condition often linked to insulin resistance and obesity, tirzepatide has not been studied in dedicated trials, but small case series and off-label use reports are emerging. The potential skeletal effects of tirzepatide in women are another area of active inquiry, given the interplay between weight loss, hormonal changes, and bone density. Retatrutide's added glucagon activity might theoretically influence bone metabolism differently, a topic we explored in a recent article on retatrutide and bone health. At ADA 2026, any sex-stratified data from retatrutide trials would be valuable for clinicians who treat women with obesity and metabolic disorders.
What's Missing: Long-Term Safety and Comparative Data
The most glaring gap in retatrutide research is the absence of long-term cardiovascular outcomes data. Tirzepatide's SURPASS-CVOT trial is ongoing, and semaglutide has already demonstrated cardiovascular benefit in the SELECT trial (Lincoff 2023). For retatrutide, the TRIUMPH-3 trial is expected to report major adverse cardiovascular events, but not until 2027 or later. Another missing piece is a direct head-to-head trial between retatrutide and tirzepatide. Without such a study, clinicians must rely on network meta-analyses that carry inherent limitations. A 2024 network meta-analysis of incretin-based therapies for weight loss estimated that retatrutide 12 mg might outperform tirzepatide 15 mg by about 3.5 percentage points in weight loss, but the confidence interval was wide (95% CI 1.2 to 5.8) (Shi 2024). The analysis included only one retatrutide trial and several tirzepatide trials, making the comparison indirect. Researchers also need more data on retatrutide in specific populations, including pregnant individuals. GLP-1 receptor agonists are generally contraindicated in pregnancy due to concerns about fetal harm, and retatrutide's glucagon component adds another layer of uncertainty. Treatment of any condition is outside the scope of this article. Diagnosis and care should be conducted by a licensed practitioner.
How to Read the ADA 2026 Data: A Clinician's Lens
When abstracts and presentations emerge from ADA 2026, several details will deserve scrutiny. First, look for the trial phase and design: phase 3 data carry more weight than post hoc analyses or open-label extensions. Second, examine the study population's baseline characteristics, including mean BMI, proportion of women, and prevalence of type 2 diabetes. Third, note the duration of follow-up; weight loss trajectories often plateau after 60-72 weeks, so shorter studies may overestimate long-term efficacy. Fourth, pay attention to the handling of missing data. Trials using intention-to-treat analysis with multiple imputation are more reliable than those reporting only completers. Fifth, assess safety signals beyond gastrointestinal events, such as changes in heart rate, liver enzymes, and bone turnover markers. The glucagon receptor agonism of retatrutide has raised theoretical concerns about hyperglycemia and increased hepatic glucose output, though the phase 2 trial showed improved glycemic control. A 2022 review of glucagon receptor biology noted that chronic activation might lead to alpha-cell hyperplasia and glucagonoma in animal models, but human relevance is unclear (Müller 2022). For women of reproductive age, any data on menstrual cycle regularity or contraceptive efficacy would be welcome, as rapid weight loss can affect ovulation and drug metabolism. Researchers conducting independent work should follow institutional protocols and ethics review where applicable.
The Honest Answer: What We Can Expect and What We Cannot
ADA 2026 will likely bring incremental advances, not a revolution. We might see 72-week data from a phase 3 retatrutide trial, possibly TRIUMPH-1 or TRIUMPH-2, which could confirm the durability of weight loss and provide more robust safety data. A prespecified comparison with tirzepatide is unlikely, but a session on indirect treatment comparisons could offer updated network meta-analyses. We may also get new information on retatrutide's effects on liver histology, building on the 2024 NASH analysis. For clinicians, the practical question is whether retatrutide's additional weight loss justifies its unknown long-term risks and likely higher cost. Tirzepatide is already facing access challenges, as discussed in our coverage of Medicare coverage changes. Retatrutide, if approved, would enter a market where prior authorization and step therapy are common. The honest answer is that retatrutide appears promising but remains investigational. Its ultimate role will depend on phase 3 efficacy, cardiovascular outcomes, and real-world safety data that will take years to accumulate. Until then, tirzepatide and semaglutide remain the evidence-based standards for pharmacologic weight management. The 2026 ADA meeting will add pieces to the puzzle, but it will not complete the picture.
Share This Article